SIGLEC-1与1型糖尿病自身免疫机制:新兴研究视角  

SIGLEC-1 and type 1 diabetes autoimmune response: Emerging research

作　　者：郭梦琪 王颜刚[2] 李树法 Guo Mengqi;Wang Yangang;Li Shufa(Department of Cardiology,the Affiliated Hospital of Qingdao University,Qingdao 266003,China;Department of Endocrinology and Metabolism,the Affiliated Hospital of Qingdao University,Qingdao 266003,China)

机构地区：[1]青岛大学附属医院心血管内科,266003 [2]青岛大学附属医院内分泌与代谢科,266003

出　　处：《中华内分泌代谢杂志》2024年第7期570-572,共3页Chinese Journal of Endocrinology and Metabolism

基　　金：国家自然科学基金(81570694,82000417);山东省自然科学基金(ZR2014HL029)。

摘　　要：Diabetologia的最新研究发现, 唾液酸结合免疫球蛋白样凝集素1(SIGLEC-1)阳性单核细胞在1型糖尿病早期发病中扮演关键角色。这些细胞主要通过干扰素信号通路, 而非传统抗原呈递方式, 激活免疫效应细胞, 进而引发胰岛炎症和破坏。这一发现为1型糖尿病的早期诊断与靶向治疗开辟了新的途径。Recent findings from Diabetologia highlight the pivotal role of sialic acid-binding immunoglobulin-type lectin 1(SIGLEC-1)positive monocytes in the early onset of type 1 diabetes.These cells activate immune effector cells primarily via the interferon signaling pathway,diverging from traditional antigen presentation methods,thereby triggering pancreatic inflammation and destruction.This discovery paves the way for novel approaches in early diagnosis and targeted therapies for type 1 diabetes.

关 键 词：SIGLEC-1 单核细胞 糖尿病 1型 自身免疫反应 干扰素信号通路 

分 类 号：R587.1[医药卫生—内分泌]